免疫细胞治疗实体瘤:聚焦双特异性抗体武装T/NK细胞OA北大核心

Adoptive cell therapy continues to drive innovation in cancer immunotherapy.Among the emerging approaches,bispecific antibody(BsAb)-armed T cell and NK cell(T/NK cell)technology leverages antibodies to specifically target tumor antigens and bridge immune effector cells,thereby endowing these cells with precise tumor-killing capabilities while overcoming the limitations of traditional therapeutic strategies.This technology is characterized by its high degree of standardization,controllable safety,and a short clinical translational cycle,demonstrating promising therapeutic potential in both solid tumors and hematologic malignancies.This article provides a comprehensive review of the advancements in chimeric antigen receptor-engineered T/NK cell(CAR-T/NK cell),tumor-infiltrating lymphocyte(TIL),and cytokine-induced memory-like NK cell(CIML NK)therapies.Particular emphasis is placed on the mechanisms of action,advantages,clinical progress,and emerging trends of BsAb-armed T/NK cell therapy.